Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling

CONCLUSIONS: Coadministration of pimecrolimus with hMSCs could interfere with the therapeutic efficacy of hMSCs in atopic dermatitis, and this is the first study that figured out the interaction of hMSCs with other drugs in cell therapy of atopic dermatitis. Therefore, this study might give rise to improvement of the clinical application of hMSCs therapy and facilitate the widespread application of hMSCs in clinical field.PMID:34454603 | DOI:10.1186/s13287-021-02547-8

Source: Cell Research - August 29, 2021 Category: Cytology Authors: Nari Shin Namhee Jung Seung-Eun Lee Dasom Kong Nam Gyo Kim Myung Geun Kook Hwanhee Park Soon Won Choi Seunghee Lee Kyung-Sun Kang Source Type: research